Filing summary
Entity and period: The supplied filing is Silverback Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022, filed August 11, 2022. It is not an ARS Pharmaceuticals, Inc. 10-Q; ARS Pharma is discussed as the proposed merger partner.
Business context and reporting period
Silverback was a clinical-stage biopharmaceutical company developing tissue-targeted therapeutics. In March 2022, it discontinued clinical programs SBT6050 and SBT6290 and redirected resources to SBT8230 and discovery work. After quarter-end, Silverback agreed to merge with ARS Pharma, developer of neffy, a needle-free epinephrine nasal spray. The proposed merger was expected to close in the fourth quarter of 2022, subject to closing conditions, including Silverback stockholder approval.
Financial performance and position
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $12.2 million | $29.1 million |
| General and administrative expense | $7.6 million | $15.4 million |
| Total operating expenses | $19.8 million | $44.5 million |
| Net loss | $19.4 million | $44.1 million |
| Net loss per share, basic and diluted | $0.55 | $1.25 |
| Operating cash used | Not separately presented | $34.9 million |
At June 30, cash and cash equivalents were $218.7 million, investments were $63.5 million, and restricted cash was $0.25 million. The filing reports cash, cash equivalents, restricted cash, and investments of approximately $282.4 million. Total liabilities were $15.2 million, including $4.9 million of lease liabilities; the former term loan had been repaid in May 2021. Stockholders’ equity was $278.8 million. Accumulated deficit was $230.3 million. There was no operating margin to report given the absence of revenue and operating losses.
Changes versus comparable periods
- Second-quarter R&D expense declined 31% year over year, largely as the company wound down SBT6050 and SBT6290; G&A rose 12%. Net loss narrowed to $19.4 million from $24.5 million.
- For the first half, R&D expense decreased 3%, while G&A increased 15%; total operating expenses rose 3% and net loss increased 2% to $44.1 million from $43.4 million.
- First-half operating cash use increased to $34.9 million from $26.3 million. Cash, cash equivalents and restricted cash declined by $35.4 million during the first half.
- Available-for-sale Treasury securities had $1.5 million of unrealized losses at June 30, 2022, recorded in other comprehensive loss.
Outlook, material events, and risks
- Management estimated that June 30 financial resources could fund operations and capital expenditures into the second half of 2026, while cautioning that this forecast depends on assumptions. The financial statements state resources were sufficient for anticipated cash requirements for at least 12 months from issuance.
- The merger agreement, signed July 21 and amended August 11, 2022, contemplated an exchange ratio of approximately 1.2441. Assuming $240 million of Silverback net cash at closing, former ARS Pharma holders were expected to own about 63% and former Silverback holders about 37% of the combined company, on a fully diluted basis. The agreement’s net-cash condition was $210 million to $255 million, with a permitted dividend for excess above $255 million.
- Silverback planned to reduce its workforce by approximately 75% by September 2, 2022, with the remainder at merger closing. It estimated $13 million of cash severance costs and $2 million of non-cash accelerated equity-award charges in the third and fourth quarters of 2022. Separately, the March restructuring was expected to cost approximately $2 million; $1.6 million had been incurred by June 30.
- Management expected R&D expense to decrease during the remainder of 2022 as development work wound down; G&A was expected to remain flat or increase due to merger-related work and asset-sale efforts.
- The merger was not assured. Failure to close could lead to another strategic transaction, asset divestitures, or liquidation; termination fees of $6 million or $10 million and expense reimbursement of up to $1.5 million could apply in specified circumstances. The filing also warns that legacy assets may not be sold on favorable terms or in time to affect merger economics.
- A securities class action relating to alleged statements about SBT6050 remained pending. Silverback said the possible loss could not be reasonably estimated and recorded no liability at June 30.
- COVID-19-related animal shortages had increased preclinical study costs and could delay development. Other disclosed risks include merger execution and workforce retention, clinical and regulatory uncertainty, financing and asset-sale outcomes, and litigation.
Important facts for investors to verify
- Confirm the filing entity: this is Silverback Therapeutics’ 10-Q, not an ARS Pharma filing.
- Check merger completion, final net cash, final exchange ratio, stockholder approval, and any changes to the expected ownership split or timing.
- Verify actual proceeds and timing from legacy-asset divestitures and the resulting treatment under the merger agreement.
- Track restructuring costs, workforce reductions, cash burn, and whether the stated runway assumptions remain valid.
- Monitor the SBT6050 securities litigation and any merger-related litigation, claims, or termination fees.